20416. SEGURIDAD Y EFICACIA DE FREXALIMAB EN EL TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE RECURRENTE: RESULTADOS A LOS 18 MESES DE LA EXTENSIÓN ABIERTA DEL ENSAYO CLÍNICO FASE 2 von Rodríguez Acevedo, B., Giovannoni, G., Granziera, C., Mao- Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Smyth, B., Djukic, B., Truffinet, P., Wallstroem, E., Vermersch, P., Montalban, X.

Volltext

Inhibition of CD40L with Frexalimab in Multiple Sclerosis von Vermersch, Patrick, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Truffinet, Philippe, Djukic, Biljana, Wallstroem, Erik, Giovannoni, Gavin

Volltext

P.6.c.009 Eplivanserin has no significant abuse potential compared to diazepam and ketamine in recreational drug users von Schoedel, K.A, Saubadu, S, Delfolie, A, Pinquier, J.L, Sellers, E.M

Volltext

PCR66 Psychometric Validation of PROMIS-Fatigue-MS-8a Questionnaire in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab von Vermersch, P., Giovannoni, G., Arnould, B., Hakimi-Hawken, N., Araujo, L., Saubadu, S., Truffinet, P., Gourlain, S., Msihid, J.

Volltext

PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab von Giovannoni, G., Vermersch, P., Arnould, B., Hakimi-Hawken, N., Araujo, L., Saubadu, S., Truffinet, P., Gourlain, S., Msihid, J.

Volltext

P1502Open-label ODYSSEY APPRISE study: interim data from the first 843 participants von Cariou, B., Averna, M., Henry, P., Gaudet, D., Lopez-Sendon, J.L., Drouot, D., Chibedi-De-Roche, D., Samuel, R., Saubadu, S., Kralova, K., Huber, K., Mertens, A., Ceska, R.

Volltext

20419. EFICACIA DE FREXALIMAB EN EL IMPACTO FÍSICO Y PSICOLÓGICO Y EN LA FATIGA EN LA ESCLEROSIS MÚLTIPLE RECURRENTE: RESULTADOS REPORTADOS EN EL MSIS-29V2 Y PROMIS-FATIGA-MS-8A EN... von Rodríguez Acevedo, B., Vermersch, P., Giovannoni, G., Saubadu, S., Truffinet, P., Arnould, B., Hakimi-Hawken, N., Minor, C., Araujo, L., Gourlain, S., Msihid, J., Montalban, X.

Volltext

Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants von Henry, P., Cariou, B., Averna, M., Gaudet, D., Lopez-Sendon, J.L., Drouot, D., Chibedi-De-Roche, D., Samuel, R., Saubadu, S., Kralova, K., Huber, K., Mertens, A., Ceska, R.

Volltext

Open-label ODYSSEY APPRISE study: interim data from the first 843 participants von Cariou, B, Averna, M, Henry, P, Gaudet, D, Lopez-Sendon, J.L, Drouot, D, Chibedi-De-Roche, D, Samuel, R, Saubadu, S, Kralova, K, Huber, K, Mertens, Ann, Ceska, R

Volltext

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M) von AHREN, B. O, DIMAS, Aniceto Leguizamo, MIOSSEC, Patrick, SAUBADU, Stéphane, ARONSON, Ronnie

Volltext

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial von Kuhle, Jens, Chitnis, Tanuja, Banwell, Brenda, Tardieu, Marc, Arnold, Douglas L, Rawlings, Andreea M, Geertsen, Svend S, Lublin, Alex L, Saubadu, Stephane, Truffinet, Philippe, Kappos, Ludwig

Volltext

Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS von Chitnis, Tanuja, Banwell, Brenda, Kappos, Ludwig, Arnold, Douglas L, Gücüyener, Kivilcim, Deiva, Kumaran, Saubadu, Stephane, Hu, Wenruo, Benamor, Myriam, Le-Halpere, Annaig, Truffinet, Philippe, Tardieu, Marc

Volltext

Efficacy of Frexalimab on Physical and Psychological Impacts and Fatigue in Relapsing Multiple Sclerosis: Findings from MSIS-29v2 and PROMIS-Fatigue-MS-8a Assessments in a Phase 2... von Vermersch, Patrick, Saubadu, Stephane, Truffinet, Philippe, Arnould, Benoit, Hakimi-Hawken, Natalia, Minor, Charles, Araujo, Lita, Gourlain, Samuel, Msihid, Jerome, Giovannoni, Gavin

Volltext

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007) von Giovannoni, Gavin, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Djukic, Biljana, Truffinet, Philippe, Wallstroem, Erik, Vermersch, Patrick

Volltext

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial von Chitnis, Tanuja, Banwell, Brenda, Kappos, Ludwig, Arnold, Douglas L, Gücüyener, Kivilcim, Deiva, Kumaran, Skripchenko, Natalia, Cui, Li-Ying, Saubadu, Stephane, Hu, Wenruo, Benamor, Myriam, Le-Halpere, Annaig, Truffinet, Philippe, Tardieu, Marc, Dubois, Benedicte, Verhelst, Helene, Bojinova-Tchamova, Veneta, Mah, Jean, Cui, Li-Ying, Fang, Fang, Hao, Yunpeng, Jiang, Li, Li, Ling, Mao, Ding'An, Qiu, Wei, Tan, Guojun, Wu, Ye, Zhang, Meini, Zhou, Hongyu, Zhou, Shuizhen, Gross-Paju, Katrin, Cheuret, Emmanuel, Deiva, Kumaran, Edan, Giles, Vukusic, Sandra, Chrousos, George, Zafeiriou, Dimitrios, Achiron, Anat, Vaknin-Dembinsky, Adi, Yamout, Bassem, Laurynaitiene, Jurate, Vaiciene-Magistris, Nerija, Bojkovski, Vladimir, Trajkova, Vesna, Chaouki, Sana, Kissani, Najib, Neuteboom, Rinze, Palavra, Filipe, Belova, Anna, Boyko, Alexey, Evdoshenko, Evgeny, Kairbekova, Ekaterina, Malkova, Nadezhda, Shumilina, Maria, Skripchenko, Natalya, Nikolic, Dimitrije, Meca-Lallana, Jose, Triki, Chahnez Charfi, Chokri, Mhiri, Gouider, Riadh, Anlar, Banu, Gücüyener, Kivilcim, Hiz, Ayse Semra, Idiman, Egemen, Turkoglu, Recai, Yapici, Zuhal, Yilmaz, Unsal, Tantsura, Lyudmyla, Voloshyna, Nataliia, Lim, Ming, Wassmer, Evangeline, Cascione, Mark, Chitnis, Tanuja, LaGanke, Christopher, Rathke, Kevin, Scagnelli, John

Volltext

150. Frexalimab in Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of Phase 3 Frexalt and Freviva Trials von Krieger, Stephen, Vermersch, Patrick, Chitnis, Tanuja, Mao-Draayer, Yang, Granziera, Cristina, Havrdova, Eva Kubala, Montalban, Xavier, Gargaun, Elena, Saubadu, Stephane, Truffinet, Philippe, Wiendl, Heinz, Giovannoni, Gavin

Volltext

152. Efficacy of Frexalimab on Physical and Psychological Impacts and Fatigue in Relapsing Multiple Sclerosis: Findings from MSIS-29v2 and PROMIS-Fatigue-MS-8a Assessments in a Pha... von Vermersch, Patrick, Saubadu, Stephane, Truffinet, Philippe, Arnould, Benoit, Hakimi-Hawken, Natalia, Minor, Charles, Araujo, Lita, Gourlain, Samuel, Msihid, Jerome, Giovannoni, Gavin

Volltext

151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension von Giovannoni, Gavin, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Smyth, Brendan, Djukic, Biljana, Truffinet, Philippe, Wallstroem, Erik, Vermersch, Patrick

Volltext

Oral venglustat in Parkinson disease patients with a mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics von Peterschmitt, M. Judith, Gurevich, Tanya, Gasser, Thomas, Saiki, Hidemoto, Isaacson, Stuart, Waters, Cheryl, Wills, Anne-Marie, Hassin-Baer, Sharon, Simuni, Tanya, Gaemers, Sebastiaan J.M., Sardi, S. Pablo, Saubadu, Stephane, Minini, Pascal, Fischer, Tanya

Volltext

Oral venglustat in Parkinson disease patients with a GBA mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics von Peterschmitt, M. Judith, Gurevich, Tanya, Gasser, Thomas, Saiki, Hidemoto, Isaacson, Stuart, Waters, Cheryl, Wills, Anne-Marie, Hassin-Baer, Sharon, Simuni, Tanya, Gaemers, Sebastiaan J.M., Sardi, S. Pablo, Saubadu, Stephane, Minini, Pascal, Fischer, Tanya

Volltext